Main Article Content
COVID-19, Diabetes Mellitus, ICU, Mortality
Backgorund and aim: There are many studies on the effects of Diabetes Mellitus on the clinical course in COVID-19 patients. Factors that increase the risk of contracting COVID-19 disease and increase disease progression have been caused, and diabetes mellitus is one of them. We aimed to evaluate the incidence of Diabetes Mellitus in patients treated in the intensive care unit in respiratory failure due to COVID-19 pneumonia, and the effect of Diabetes Mellitus on the length of stay in intensive care and mortality.
Methods: Our study is a single-center retrospective study. The study includes patients hospitalized in our COVID intensive care unit between March 16, 2019, and May 16, 2020 Patients over 18 years of age with and without a history of Diabetes Mellitus were compared in 2 groups. Demographic data of the patients, length of stay in the intensive care unit, respiratory support methods, presence of other comorbid diseases, effects of Diabetes Mellitus to mortality in ICU were recorded.
Results: The information of 150 patients was obtained in the COVID-19 intensive care units of our hospital. Diabetes Mellitus was detected in 49 of the patients hospitalized in intensive care. 34.7% of these patients were female and 65.3% were male. There was no significant difference in survival in both groups (p = 0.942). The BMI of the patients with Diabetes Mellitus was 27.07 ± 2.55, significantly higher (p = 0.005). Intensive care stay periods were similar in both groups. The presence of hypertension was significantly higher in those with Diabetes Mellitus (p = 0.000). There was no statistically significant difference between respiratory support methods.
Conclusions: Diabetes Mellitus did not affect the duration of stay in the intensive care unit and mortality in patients who were followed up and treated in the intensive care unit due to COVID-19 pneumonia.
2. Wu Zunyou, McGoogan Jennifer M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13): 1239.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054-1062.
4. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91-95
5. Katulanda P, Dissanayake HA, Ranathunga I, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. Diabetologia 2020; 63(8):1440-1452.
6. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes & Endocrinology 2020; 8(6):546-550.
7. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
8. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy 2020;75(7):1730-1741.
9. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020:323(13):1239-1242.
10. Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med. 2006;23(6):623–628.
11. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID- 19? A meta-analysis. Diabetes Metab Syndr 2020;14(4):535-545.
12. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–2059.
13. Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: systematic review and meta-analysis. J Infect 2020;81:e84–86.
14. Hussain, A., Mahawar, K., Xia, Z., Yang, W., & EL-Hasani, S. RETRACTED: Obesity and mortality of COVID-19. Meta-analysis. Obesity Research & Clinical Practice 2020;14(4): 295–300.
15. Huang J. F., Wang X. B., Zheng K. I., et al. Letter to the Editor: Obesity hypoventilation syndrome and severe COVID-19. Metabolism 2020;108:1542-1549.
16. Cheng L., Li H., Li L., et al. Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis. Journal of Clinical Laboratory Analysis 2020; 34(10):23618
17. Tan C, Huang Y, Shi F, et al. C-reactive protein correlates with CT findings and predicts severe COVID-19 early. J Med Virol 2020; 92(7):856-862.
18. Yan Y, Yang Y, Wang F, et al. Clinical characteristics and outcomes of patients with severe covid-19 with Diabetes. BMJ Open Diab Res Care 2020; 8(1): e001343.
19. Moutschen M.P., Scheen A.J., Lefebvre PJ. Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections. Diabete Metab 1992;18(3):187-201.
20. Grasselli G., Greco M., Zanella A., et al.Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Internal Medicine 220;180(10):345.
21. Orioli L., Hermans M. P., Thissen J. P., Maiter D., Vandeleene B., Yombi J. C. (2020). COVID-19 in diabetic patients: Related risks and specifics of management. Annales d'endocrinologie 2020;81(2-3):101–109.